What is Zacks Research’s Forecast for CRDF FY2027 Earnings?

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Investment analysts at Zacks Research lowered their FY2027 EPS estimates for Cardiff Oncology in a note issued to investors on Monday, March 2nd. Zacks Research analyst J. Vandermosten now expects that the company will earn ($0.75) per share for the year, down from their prior forecast of ($0.74). The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.99) per share.

A number of other equities analysts also recently commented on CRDF. Noble Financial assumed coverage on Cardiff Oncology in a research report on Monday, January 5th. They set an “outperform” rating and a $12.00 price objective on the stock. Wall Street Zen raised Cardiff Oncology from a “sell” rating to a “hold” rating in a research note on Wednesday. Piper Sandler lowered their price target on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Cardiff Oncology in a report on Wednesday, January 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Wednesday, January 21st. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $10.10.

Cardiff Oncology Price Performance

Shares of Cardiff Oncology stock opened at $1.89 on Wednesday. The stock has a market cap of $129.20 million, a P/E ratio of -2.74 and a beta of 1.32. The stock’s 50 day simple moving average is $2.28 and its 200-day simple moving average is $2.24. Cardiff Oncology has a 1-year low of $1.48 and a 1-year high of $4.56.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.07. The firm had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.13 million. Cardiff Oncology had a negative net margin of 7,733.22% and a negative return on equity of 82.01%.

Institutional Trading of Cardiff Oncology

Hedge funds and other institutional investors have recently modified their holdings of the business. Laurion Capital Management LP lifted its position in Cardiff Oncology by 7.3% in the fourth quarter. Laurion Capital Management LP now owns 2,646,738 shares of the company’s stock valued at $7,437,000 after buying an additional 180,866 shares during the last quarter. Acorn Capital Advisors LLC raised its stake in shares of Cardiff Oncology by 39.3% in the 3rd quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock valued at $4,042,000 after acquiring an additional 553,317 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Cardiff Oncology by 7.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock worth $4,723,000 after acquiring an additional 104,409 shares during the last quarter. Franklin Resources Inc. acquired a new position in Cardiff Oncology during the fourth quarter worth $3,388,000. Finally, State Street Corp boosted its holdings in Cardiff Oncology by 4.0% in the fourth quarter. State Street Corp now owns 1,191,647 shares of the company’s stock valued at $3,349,000 after purchasing an additional 45,288 shares during the period. 16.29% of the stock is owned by institutional investors and hedge funds.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.